Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Darkfin Labs is a longevity-focused biotech skincare company that develops advanced anti-aging and preventative skincare products. Founded by stem cell biologist Annalina Che, the company's formulations are built around L-01™ (also known as DL-01™), a proprietary, plant-grown growth factor peptide complex inspired by stem cell signaling science. This complex contains precisely dosed, bio-designed growth factors—including epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), and insulin-like growth factor 1 (IGF-1)—produced via plant-based protein expression and encapsulated in a plant-derived liposomal delivery system. Darkfin Labs' flagship product, the Longevity Protocol Serum + Moisturizer, is a multitasking daily formula designed to target multiple pathways of skin aging, such as collagen decline, chronic inflammation, and barrier impairment. The company's research arm, Stemtology, collaborates with Microsoft's AI Co-Innovation Labs to leverage agentic AI and machine learning to accelerate regenerative medicine and biomimetic discovery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Darkfin Labs.